Toxicidad cutánea asociada a la administración de paclitaxel

Ignacio, Rodrigo; Pérez, María Jesús Rubio; López, R. Albornoz; Ruiz, J. Abellón

doi:10.1016/s1130-6343(08)75954-3

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, while doxorubicin (DOX), which is a chemotherapeutic agent widely used for treatment of cancer (particularly for breast cancer, lung cancer, leukaemia, and various other solid tumours), [3] shows powerful anti‐tumour effects on each step of the cell cycle and can inhibit the formation of topoisomerase‐II while preventing DNA replication in tumour cells, [4] the clinical use of DOX is limited by its cardiotoxicity. A similar problem also occurs in other chemotherapeutic agents such as paclitaxel [5–10] and 5‐fluorouracil, [11–13] whose wide clinical application has been impeded by their poor aqueous solubility and high systemic toxicity. Development of carriers that can enhance the efficiency and safety of drug treatment is, therefore, in dire need [14–20] …”

Section: Introductionmentioning

confidence: 90%

Development and Characterization of Montmorillonite‐Based Hybrid Materials for pH‐Responsive Drug Delivery

et al. 2021

View full text Add to dashboard Cite

This study reports the development of montmorillonite (MMT)‐based hybrid systems for pH‐responsive drug delivery. During fabrication, MMT is first modified with dimethyl sulfoxide (DMSO) and methanol (MeOH), with the generated hybrid materials being designated as MMTDMSO and MMTMeOH, respectively. The hybrid materials are then intercalated with DOX for drug delivery purposes. Results of XRD and DSC reveal that DOX is successfully intercalated into the MMT interlayers. In vitrodrug release studies of the DOX‐loaded hybrid materials are investigated at pH 4.5 and 7.4 at 37 °C. The cytotoxicity of the materials is studied in vitro by using human breast cancer cells (MCF‐7) as a model. Results suggest that our hybrid materials are carriers enabling effective, sustained and controlled drug release.

show abstract

Section: Introductionmentioning

confidence: 90%

Development and Characterization of Montmorillonite‐Based Hybrid Materials for pH‐Responsive Drug Delivery

et al. 2021

View full text Add to dashboard Cite

show abstract

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report

Cirauqui

Garcı́a

et al. 2014

J Med Case Reports

View full text Add to dashboard Cite

IntroductionTaxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences between paclitaxel and other drugs.Case presentationWe describe the case of a 55-year-old Caucasian woman with locally advanced breast cancer treated with neoadjuvant therapy who developed secondary skin toxicity due to delayed hypersensitivity to taxanes. She received Adriamycin® (doxorubicin), cyclophosphamide and docetaxel and developed toxicity that promoted treatment delay and a switch to weekly paclitaxel. After the third and fourth weeks of treatment, paclitaxel toxicities also induced treatment delay and paclitaxel was switched to nanoparticle albumin-bound paclitaxel. She completed the five planned nanoparticle albumin-bound paclitaxel cycles with acceptable tolerability (including persistent grade 2 neuropathy) and without dose delay or adjustments. Clinical response was achieved although pathological response was not good.ConclusionsNanoparticle albumin-bound paclitaxel treatment is a good option for patients with breast cancer with taxanes-related skin toxicity. This drug allows the treatment to be completed with acceptable tolerance in our case.

show abstract

Toxicidad cutánea asociada a la administración de paclitaxel

Cited by 2 publications

References 3 publications

Development and Characterization of Montmorillonite‐Based Hybrid Materials for pH‐Responsive Drug Delivery

Development and Characterization of Montmorillonite‐Based Hybrid Materials for pH‐Responsive Drug Delivery

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report

Contact Info

Product

Resources

About